Efficacy of nucleoside analogues antiviral therapy on clinical outcome for HBV-related primary hepatic carcinoma patients after hepatectomy
10.3969/j.issn.1006-5725.2016.15.014
- VernacularTitle:核苷（酸）类似物抗病毒治疗对乙型肝炎病毒相关性肝癌术后临床转归的影响
- Author:
Hongbing YAO
;
Mingbo WEN
;
Yunpeng HUA
;
Gao HUANG
;
Guihua LI
- Publication Type:Journal Article
- Keywords:
Nucleoside analogues;
HBV-related primary hepatic carcinoma;
Antiviral;
Hepatectomy
- From:
The Journal of Practical Medicine
2016;32(15):2468-2470
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of nucleoside analogues (NAs) antiviral therapy on clinical outcome for hepatitis B virus (HBV)-related primary hepatic carcinoma patients after hepatectomy. Methods The clinical data of 156 HBV-related primary hepatic carcinoma patients after hepatectomy were retrospectively analyzed..According to whether accepted postoperative antiviral treatment, all patients were divided into control group (n = 80)and observation group (n = 76). The serum HBV DNA capacity, recurrence-free survival (RFS)and overall survival (OS)were compared between two groups. Results One week, 1 month, 2 months and 3 months after operation , the serum HBV DNA capacity of observation group was significantly lower than that of control group(P < 0.05). One year, 3 years and 5 years after operation, intergroup comparison of RFS rate of both groups showed statistical significance (P < 0.05) and 1 year, 3 years and 5 years after operation, the difference of OS rate of both groups indicated statistical significance (P < 0.05). Conclusion Standard NAs antiviral treatment for HBV-related primary hepatic carcinoma patients after hepatectomy ,can improve prognosis and prolong survival time. The inhibition the HBV copy active may be its mechanism.
